LX7101 (0.125%)
LX7101.7-101-OAG
Phase 2 small_molecule completed
Quick answer
LX7101 (0.125%) for Primary Open-angle Glaucoma is a Phase 2 program (small_molecule) at LEXICON PHARMACEUTICALS, INC. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- LEXICON PHARMACEUTICALS, INC.
- Indication
- Primary Open-angle Glaucoma
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed